The study team must comply with all applicable regulations for document retention, storage and disposal once the research study has been completed. Further information on the processes for studies that handle investigational drugs and devices, or include external devices, such as hard-drives or flash-drives, are also explained.
Information regarding the course of action for study close-outs, study terminations and financial close-outs for a research study. Includes details pertaining to the IRB, GCO, IDS, EPIC and other ancillary departments.
How study teams can prepare for internal audits, by the Research Compliance Office at ISMMS, or external agency audits by the FDA or OHRP, and routinely monitoring visits by the study sponsor or CRO. The purpose of these visits are to ensure the research study is compliant with the study protocol and the GCP/HSP regulatory requirements.
Information on the financial management of industry initiated clinical trials, including generating a fund number, invoicing, study and research subject payments.
Information on managing and maintaining regulatory compliance throughout the duration of the research study. This includes regulatory compliance resources, essential documents for the study’s regulatory binder, GCO annual submissions, IRB modifications and continuations.
Information regarding translation and interpretation services for research studies.
Information on the process for registering and managing research studies in Epic, the electronic medical record system used at MSHS.
Prior to study enrollment, the study monitor on behalf of the sponsor will conduct a Site Initiation Visit (SIV) to provide the principal investigator and the study team training on the protocol, procedures, processes and monitoring plan.
Instructions are provided for the Grants & Contracts Office InfoEd submission process, including steps to finalize and submit the application, contact information for the departmental assigned GCO specialist, and approval routing process.
Guidance on the submission process pertaining to For-Profit (Industry) clinical trial agreements to the Financial Administration of Clinical Trials Services (FACTS) Office. Further detail on budget development and negotiations are also provided.